Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 6:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 2,080 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Dementia Alzheimers Clear all
Completed No phase listed Observational

Development and Decline of Brain and Cognition Through the Life Span

NCT00880451
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 16, 2021 · Synced Oct 4, 2026, 6:52 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Evaluation of [123I]CLINDE and SPECT as a Marker of Inflammation in Subjects With PD or AD and in Healthy Subjects

NCT00612872
View directory record Official record
Conditions
Parkinson Disease, Alzheimer Disease, Healthy Controls, Multiple Sclerosis
Interventions
[123I]CLINDE
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
30 Years to 50 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 3, 2019 · Synced Oct 4, 2026, 6:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of CTS21166 to Treat Alzheimer Disease

NCT00621010
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
CTS21166 (ZPQ-21166)
Drug
Lead sponsor
CoMentis
Industry
Eligibility
22 Years and older · Male only
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 9, 2008 · Synced Oct 4, 2026, 6:52 AM EDT
Completed Not applicable Interventional

A Program to Reduce Inappropriate Medications Among Older Adults With Alzheimer's Disease: Implementation Phase 2

NCT06368115
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Educational Materials
Other
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
50 Years and older
Enrollment
11,375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 4, 2026, 6:52 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Pilot Study: Lipoic Acid and Omega-3 Fatty Acids for Alzheimer's Prevention

NCT01780974
View directory record Official record
Conditions
Treated Hypertension
Interventions
Lipoic Acid plus Omega-3 Fatty Acids, Placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
55 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 7, 2017 · Synced Oct 4, 2026, 6:52 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Translating a Dementia Caregiver Intervention Into a Mobile Application

NCT04330482
View directory record Official record
Conditions
Dementia, Alzheimer Disease, Caregiver Burnout
Interventions
CARE-Well App, Internet Links
Behavioral
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
2
States / cities
Kingston, Rhode Island • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 4, 2026, 6:52 AM EDT
Completed Phase 4 Interventional Results available

Lithium As a Treatment to Prevent Impairment of Cognition in Elders

NCT03185208
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Lithium Carbonate, Placebo oral capsule
Drug
Lead sponsor
Ariel Gildengers, MD
Other
Eligibility
60 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 4, 2026, 6:52 AM EDT
Completed Phase 1 Interventional

Gene Therapy for Alzheimer's Disease Clinical Trial

NCT00017940
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Human Nerve Growth Factor
Genetic
Lead sponsor
The Shiley Family Trust
Other
Eligibility
50 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2003
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Dec 11, 2009 · Synced Oct 4, 2026, 6:52 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Feasibility of the SmartPrompt for Improving Everyday Function in Dementia

NCT04313582
View directory record Official record
Conditions
Dementia, Dementia, Vascular, Dementia Alzheimers, Dementia, Mixed, Dementia, Mild, Dementia of Alzheimer Type, Mild Cognitive Impairment, Mild Dementia
Interventions
SmartPrompt smartphone application
Behavioral
Lead sponsor
Temple University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 16, 2024 · Synced Oct 4, 2026, 6:52 AM EDT
Completed Phase 1 Interventional

CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease

NCT00087789
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
CERE-110: Adeno-Associated Virus Delivery of NGF
Genetic
Lead sponsor
Sangamo Therapeutics
Industry
Eligibility
50 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
2
States / cities
San Diego, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 10, 2022 · Synced Oct 4, 2026, 6:52 AM EDT
Recruiting Not applicable Interventional

Effect of Physiologic Insulin Administration on Insulin Sensitivity and Cognition

NCT07265323
View directory record Official record
Conditions
Alzheimer s Disease, Alzheimer Blood Biomarkers, Insulin Sensitivity
Interventions
Physiological Insulin Intervention
Other
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Oct 4, 2026, 6:52 AM EDT
Completed Phase 2Phase 3 Interventional

Study Evaluating the Safety, Tolerability, and Efficacy of Lecozotan SR in Outpatients With Alzheimer's Disease

NCT00277810
View directory record Official record
Conditions
Alzheimer Disease
Interventions
lecozotan SR (SRA-333)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
50 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
33
States / cities
Phoenix, Arizona • Tucson, Arizona • Costa Mesa, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2020 · Synced Oct 4, 2026, 6:52 AM EDT
Not listed No phase listed Observational

Digital Evaluations and Technologies Enabling Clinical Translation for AD

NCT05385913
View directory record Official record
Conditions
Alzheimer Disease, Early Onset
Interventions
Multivitamin-no intervention
Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
65 Years and older
Enrollment
200 participants
Timeline
2022 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 6, 2023 · Synced Oct 4, 2026, 6:52 AM EDT
Enrolling by invitation No phase listed Observational

F 18 T807 Tau PET Imaging in Dominantly Inherited Alzheimer's Network (DIAN Project)

NCT02414178
View directory record Official record
Conditions
Alzheimer Disease
Interventions
F 18 T807
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 4, 2026, 6:52 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Dominantly Inherited Alzheimer Network (DIAN)

NCT00869817
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2026
U.S. locations
8
States / cities
Jacksonville, Florida • Indianapolis, Indiana • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 4, 2026, 6:52 AM EDT
Completed No phase listed Observational

Tau Imaging in Young Onset Dementia

NCT02289118
View directory record Official record
Conditions
Alzheimer's Disease, Early Onset, Logopenic Progressive Aphasia, Posterior Cortical Atrophy (PCA)
Interventions
[18F]-T807 imaging tracer
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
45 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 25, 2020 · Synced Oct 4, 2026, 6:52 AM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Participants With Dementia of the Alzheimer's Type

NCT02442778
View directory record Official record
Conditions
Agitation in Participants With Dementia of the Alzheimer's Type
Interventions
AVP-786-18, Placebo, AVP-786-28, AVP-786-42.63
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
522 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
79
States / cities
Chandler, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 55 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2022 · Synced Oct 4, 2026, 6:52 AM EDT
Completed Phase 3 Interventional

Serotonergic Pharmacotherapy for Agitation of Dementia

NCT00009204
View directory record Official record
Conditions
Dementia, Alzheimer Disease, Dementia, Vascular
Interventions
Citalopram [Celexa], Perphenazine [Trilafon]
Drug
Lead sponsor
Bruce Pollock
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2002
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 16, 2017 · Synced Oct 4, 2026, 6:52 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

QTc Study of Rosi XR in Healthy Volunteers

NCT00884533
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Rosi XR, Placebo, Moxifloxacin
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 17, 2015 · Synced Oct 4, 2026, 6:52 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Mobile Phone App for Depression and Anxiety in Young Men Who Are Attracted to Men

NCT02072252
View directory record Official record
Conditions
Depressive Symptoms, Anxiety Generalized
Interventions
Mobile Phone Application
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
17 Years to 20 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced Oct 4, 2026, 6:52 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Brain Effects of Gamma Frequency Sensory Stimulation (40Hz Light, Sound and Other Devices)

NCT07496918
View directory record Official record
Conditions
Cognitively Healthy People, Alzheimer Disease
Interventions
GENUS, Tactile GENUS
Device
Lead sponsor
Massachusetts Institute of Technology
Other
Eligibility
18 Years to 100 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 4, 2026, 6:52 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)

NCT04602624
View directory record Official record
Conditions
Alzheimer Disease, Cognitive Dysfunction, Mild Dementia
Interventions
SAGE-718
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
50 Years to 80 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
10
States / cities
Phoenix, Arizona • Redlands, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Oct 4, 2026, 6:52 AM EDT
Completed Not applicable Interventional Results available

Reducing CVD Risk in Caregivers: A Brief Behavioral Activation Intervention

NCT01802554
View directory record Official record
Conditions
Depressive Symptoms, Inflammation
Interventions
Pleasant Events Program (PEP), Information Support (IS)
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
55 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 13, 2016 · Synced Oct 4, 2026, 6:52 AM EDT
Completed Phase 2 Interventional Results available

Follow up 18F-AV-1451 Scan in Confirmatory Cohort Subjects From Study 18F-AV-1451-A05

NCT02795780
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Flortaucipir F18, PET Scan
Drug · Procedure
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
22
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2020 · Synced Oct 4, 2026, 6:52 AM EDT